Caixin
May 11, 2022 08:11 PM
BUSINESS

BioNTech’s Covid Vaccine Safety Trial in China Completed Four Months Ago, Registry Shows

China is studying the use of mRNA vaccines on the mainland to complement domestically produced shots. Photo: VCG
China is studying the use of mRNA vaccines on the mainland to complement domestically produced shots. Photo: VCG

German vaccine developer BioNTech SE completed a safety trial of its mRNA Covid shot in China in January though results aren’t available publicly yet, a medical database showed Tuesday.

The messenger RNA vaccine — distributed by Pfizer Inc. outside Greater China — is one of the most widely used worldwide, with robust data showing its effectiveness and safety in late-stage trials published in multiple peer-reviewed journals.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code